HALEOSLABS vs KREBSBIO: Stock Comparison

Haleos Labs Limited vs Krebs Biochemicals and Industries Limited

Live data: 22 July 2026, 3:07 PM IST • Source: NSE and company filings

Haleos Labs Limited is the larger company by market capitalisation. Haleos Labs Limited shows a higher dividend yield, a higher ROCE and a higher net margin, while Krebs Biochemicals and Industries Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Haleos Labs Limited and Krebs Biochemicals and Industries Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, HALEOSLABS is more favourable on 5 of 11 scored metrics and KREBSBIO on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
HALEOSLABS is the larger company
₹484 Cr vs ₹117 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 27.94x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 2.27x
EPS
HALEOSLABS has higher earnings per share
₹57.3 vs ₹-7.85
Dividend Yield
HALEOSLABS has a higher dividend yield
0.1% vs 0%
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs 0%
Qtr Sales Growth
KREBSBIO has stronger quarterly sales growth
11.6% vs -15.7%
Qtr Profit Growth
KREBSBIO has stronger quarterly profit growth
71.7% vs -85.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHALEOSLABSKREBSBIO
SectorHealthcare
IndustryPharmaceuticals

Price

MetricHALEOSLABSKREBSBIO
Live Price₹1,522.4₹53.41
Day Change-3.09%-3.03%
Volume2811,997
52-Week High₹1,774₹82.49
52-Week Low₹1,181₹38.33
Distance from 52W High-14.18%-35.25%

Valuation

MetricHALEOSLABSKREBSBIO
Market Cap₹484 Cr₹117 Cr
P/E Ratio27.94x0x
P/B Ratio2.27x0x
EPS₹57.3₹-7.85
Book Value₹706₹-75.5
Dividend Yield0.1%0%

Growth

MetricHALEOSLABSKREBSBIO
Revenue Growth (TTM YoY)0%11.6%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-15.7%11.6%
Qtr Profit Growth-85.2%71.7%

Profitability & Leverage

MetricHALEOSLABSKREBSBIO
ROE8.44%
ROCE9.91%-15.4%
Net Margin5.33%-71.35%
Operating Margin13.4%-23%
Debt to Equity0.52x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricHALEOSLABSKREBSBIO
Promoter Holding72.11%72.74%
FII Holding0%0.5%
DII Holding0.31% 0.01 pp0%
Public Holding27.58% 0.02 pp26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Haleos Labs Limited and Krebs Biochemicals and Industries Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.